Movano Health (Ticker: MOVN) held its Q4 2023 earnings call, highlighting the commercial success of the Evie Ring and detailing plans for expansion and new product development. Despite exceeding sales expectations, the company faced production challenges due to capital constraints.
However, with a recent $24 million private placement and a strategic investment from a Tier 1 medical device company, Movano Health is well-positioned to pursue FDA clearances, expand its product line, and target business-to-business (B2B) opportunities. The company reported a Q4 operating loss of $6 million but is optimistic about its future, with over 8,000 potential buyers on the Evie Ring waitlist and plans to relaunch the product.
Key Takeaways
- Movano Health's Evie Ring launch surpassed expectations, with a waitlist of over 8,000 potential buyers.
- The company closed a $24 million private placement, bolstered by a $3 million strategic investment from a top-tier medical device company.
- Focus on achieving FDA clearance for pulse rate and blood oxygen monitoring, launching Evie Med, and exploring B2B markets.
- Successful clinical trial for wearable blood pressure monitoring device, meeting FDA accuracy criteria.
- Plans to expand product offerings beyond the Evie Ring and Evie Med, targeting noninvasive blood glucose monitoring for diabetes patients.
- Operating loss of $6 million for Q4 2023, with $6.1 million in cash and cash equivalents as of December 31, 2023.
- Intent to connect future products with Apple (NASDAQ:AAPL) Health and explore various form factors and measurement sites for blood pressure and glucose monitoring.
Company Outlook
- Movano Health aims to achieve FDA clearance for additional health monitoring features and launch Evie Med.
- The company is targeting B2B opportunities in clinical trials, payer, and remote patient monitoring markets.
- Expansion plans include multi-analyte sensing and additional FDA clearances.
Bearish Highlights
- Movano Health faced capital constraints and operational challenges, impacting volume production.
- The company reported a $6 million operating loss for the fourth quarter of 2023.
Bullish Highlights
- Strategic investment from a Tier 1 medical device company demonstrates confidence in Movano Health's technology.
- Successful clinical trial for blood pressure monitoring device, with potential for inclusion in the Evie product suite.
Misses
- Despite the successful launch, production volume was limited due to earlier capital and operational hurdles.
Q&A Highlights
- Movano Health is considering various form factors for its products, including rings, bands, and potentially finger-based blood pressure monitoring.
- The company is flexible in its approach to noninvasive glucose monitoring, exploring different measurement sites.
- There is an intention to integrate future products with platforms like Apple Health for a more connected health experience.
Movano Health's earnings call painted a picture of a company at the cusp of significant growth, with a clear strategy to overcome its initial production challenges and capitalize on the success of its Evie Ring. With a strong financial backing and a robust product pipeline, Movano Health is poised to make a notable impact in the wearable health technology market.
InvestingPro Insights
Movano Health (Ticker: MOVN) has demonstrated a robust strategy for growth, as outlined in their recent earnings call. To further understand the financial health and market position of the company, let's consider key metrics and insights from InvestingPro.
InvestingPro Data shows a market capitalization of $29.72 million, indicating the company's current valuation within the market. Notably, the Price / Book ratio as of the last twelve months ending Q4 2023 stands at 8.62, which suggests that the stock is trading at a premium compared to the company's net asset value. This can often be the case for growth companies that investors believe have significant potential.
Despite the optimistic outlook presented in the earnings call, the company's financials reveal challenges. The Price to Earnings (P/E) Ratio, which is negative at -1.02, indicates that Movano Health is not currently profitable. Furthermore, the company has experienced a significant price decline over the past year, with a 1 Year Price Total Return of -54.16%.
InvestingPro Tips highlight that Movano Health holds more cash than debt on its balance sheet, which is a positive sign for financial stability. However, it is also quickly burning through cash, a situation that investors should monitor closely, especially as the company continues to invest in product development and seeks FDA clearances.
For readers interested in deeper analysis and additional InvestingPro Tips, including the company's cash burn rate and potential for profitability, visit https://www.investing.com/pro/MOVN. There are 11 additional InvestingPro Tips available, providing a comprehensive look into Movano Health's financial health and market potential.
To gain full access to these insights, use the coupon code PRONEWS24 for an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. This offer can help investors make more informed decisions by providing a detailed understanding of Movano Health's financial situation and market performance.
Full transcript - Movano (MOVE) Q4 2023:
Operator: Greetings, and welcome to the Movano Health Fourth Quarter 2023 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, David Barnard, with LHA Investor Relations. Thank you, David. You may begin.
David Barnard: Thanks, Paul. Good afternoon, everyone, and thank you for joining us today. Movano Health, CEO; John Mastrototaro will open today's call with prepared remarks about the progress the company made during the fourth quarter of 2023 and in recent weeks. Today's guest speaker will be Michael Soule, Vice President of Business Development, who will provide some remarks on the company's B2B activities, followed again by John and then CFO, Jay Cogan, will provide highlights of the company's quarterly operating results and current financial position. Then we'll open the call for Q&A. John, Jay and Michael will be joined by our Chief Marketing Officer, Tyla Bucher, and Vice President of Product Strategy, Stacy Salvi. Movano Health issued a news release this afternoon dealing both fourth quarter and full year 2023 financial results. Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call based on current expectations. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties, and actual results may be materially different from such statements. These risks and uncertainties are detailed in the Risk Factors section of Movano Health's filings with the Securities and Exchange Commission specifically in the company's Forms 10-Q and 10-K. Except as otherwise required by federal securities laws, Movano Health disclaims any obligation to update or make revisions to such forward-looking statements contained herein or elsewhere to reflect chain expectations with regards to those events, conditions and circumstances. With that, I'll turn the call over to CEO, John Mastrototaro.
John Mastrototaro: Good afternoon, everyone. Movano Health is at a critical inflection point, and I'm excited to speak with you today about our progress. First, we commercially launched the Evie ring last November ahead of Black Friday, garnering strong views on the aesthetics, technology and form factor. Demand for the Evie Ring bar exceeded our expectations. However, our ability to attain volume production to meet demand was hindered most significantly by capital constraints and to a lesser degree, we experienced some operational challenges. So we paused our ring order intake. I'm pleased to share our team has been diligently addressing the issues and are nearing resolution. During this time, in just 6 weeks, we have amassed a wait list of over 8,000 potential buyers organically without any paid marketing. Our initial direct-to-consumer launch is providing incredibly valuable user feedback as we drive toward both continued D2C growth and multiple business-to-business opportunities. This afternoon, we closed on a $24 million private placement, including a $3 million strategic seed investment from a Tier 1 multibillion-dollar global medical device company. This is a pivotal moment in our company's journey. We're thrilled to partner with this leader in health care and look forward to potential future collaborations. As we highlighted in our press release earlier this week, this strategic investor is keenly interested in the Evie Ring and our proprietary millimeter wave radio frequency technology and then underscores the vast potential of our innovative approach delivering medical grade data to both consumers and enterprises. We're also fortunate to have had the broad participation in the private placement from Movano health management team and Board of Directors totaling more than $3.6 million. Now with the new financing, we are set up to scale commercial production proceed further along the regulatory pathway and pursue multiple market opportunities that should deliver shareholder value. Our goal is to deliver both the consumer and FDA-cleared wearable that combines accessibility, personalization and style with the recognized capabilities of a medical device. Our highest priorities are as follows: one, to achieve our first FDA clearance for pulse rate and blood oxygen monitoring, which sets the stage for our brand expansion to Evie Med. Two, on the heels of this clearance to bring key B2B opportunities to fruition. And three, to accelerate our clinical trials for couples blood pressure and noninvasive glucose monitoring, establishing the foundation to develop additional commercial products forging our proprietary technology. Movano Health is using Evie to set new standards for the possibilities of what wearable health technology can do. We plan to serve consumers through both D2C and B2B channels where regardless of the ate point, our user is ultimately always a consumer wearing a ring. As such, the Evie Ring wireless product is a valuable step on our path to broader commercialization. We're already learning what consumers like and want, and this critical information will help us achieve higher adoption and engagement from future users. Based on early feedback, we've made several software updates to improve the overall experience, including minimizing use of the green LED light and improving the accuracy of our sleep tracking. In March, we launched our Insight Engine, which is the first step to offering our customers personalized insights, which leverage an AI-based framework, correlate disparate data types. We plan to be judicious with our capital position and methodical in our approach to build out our direct-to-consumer and business-to-business market opportunities. In preparation for our B2B launch, we must secure FDA clearance and improve our scale and volume production capabilities. We also plan to execute several initiatives in the next few months, developing an Android version of the app, building sufficient finished inventory to ensure quick order fulfillment and bolstering our customer service capacity. Regarding the FDA pathway, we've been strategically focused on pulse rate and blood oxygen saturation monitoring often referred to as SpO2. In the first quarter of 2024, and we used our commercial ring in a second hypoxia trial with UCSF, in which each subject were 4 Evie Rings, 2 1 fingers and 2 held on fingertips. When evaluating accuracy versus arterial blood gas levels, the 4 Evie Rings achieved a root-mean-square error of 2.46%, well within the FDA guidance of 3.5%. In addition, our rings accuracy also exceeded that of 2 commercially available hospital-grade reference pulse oximeters, one of which failed to meet the FDA standard for accuracy. Later this month, we plan to present this confirmatory data and address the outstanding FDA comments from our prior submission. We believe taking these steps will put Movano Health on track to read the decision regarding the 510(k) clearance in July 2024. We look forward to continuing to work closely with the FDA throughout the review process. In preparation for a positive FDA decision, we have been planning the launch of Evie Med, the medical device version of the ring. It's important to note that because the Evie ring and Evie Med will be the same physical ring, production costs remain the same. The primary difference is that Evie Med will include labeling for the FDA-cleared features as well as some modifications to the app experience. As mentioned earlier, our Evie user base and customer feedback support sizable B2B opportunities. I'll now hand the call over to Michael Soule, our VP of Business Development, to discuss our efforts.
Michael Soule: Thank you, John. As noted, there are numerous B2B opportunities for Evie Med. We are actively engaged with potential partners that are performing various beta tests with Evie to assess form and function. Today, I will review 3 of the distinct market segments beyond the medical device partnership that we announced earlier this week. First, the clinical trial market consists of pharmaceutical companies that need to gather data from FDA-cleared devices as part of their drug trials for FDA and other regulatory submissions. We are poised to dominate the $2 billion market annually of FDA-cleared wearables with minimal competition. Currently, trials are in person, cumbersome, expensive enough are suboptimal as they don't capture the subjects in actual realized situations. We believe Evie Med would improve compliance, lower costs significantly and enable quicker enrollment, better data and improved quality of results. Presently, we are in discussions with 5 top-tier pharma companies, one of which has beta tested Evie. All of these potential partners are excited about the prospects for an FDA-cleared low-cost and convenient wearable to take the place of other devices presently used. Second, the payer market consists of insurers that represent more than 130 million patients with chronic diseases, often with comorbidities who have poor and/or unreliable monitoring options. Evie Med would provide an easy-to-implement solution for early detection of dangerous health risks and for the prevention that could greatly reduce costly disease interventions. Already, we have traction with one of the top 3 U.S. payers that covers approximately 50 million lives. If Evie Med is used by just 1% of this insurer's population, that equates to more than 0.5 million rings. The third market I wanted to highlight is the rapidly growing remote patient monitoring channel or RPM. This market barely existed 4 years ago. However, COVID unlocked the reality that health care can reduce the need for in-office visits, expand access and reduce costs. We believe Evie Med will be able to automate more complete and accurate data result in RPM solution with meaningful advantages over RPM products in the market today. Our wearable technology is in beta testing with a leading U.S. RPM company that serves over 450 health care organizations and is the exclusive platform for one of the largest medical device companies in the world. This is just the tip of the iceberg. Other large B2B opportunities include applications and condition management for cardiovascular, metabolic, obesity and pulmonary patients, which, in aggregate, we've identified as a $20 billion per year market opportunity and corporate wellness with an identified TAM of $14 billion. Additionally, we fully anticipate the Evie Med introduction will drive more consumer awareness, leading to greater D2C adoption. I'll now turn the call back to John.
John Mastrototaro: Thanks, Michael. Our product development plan extends far beyond Evie and Evie Med. We're deeply invested in multi-analyte sensing and pursuing additional FDA clearances with further research and respiration rate for temperature and a solution to address sleep disturbances. Some of these metrics may only require a software update while others may require new hardware components or potentially different form factors. Our commitment to innovation and improving health monitoring and intervention has fueled 6 years of intensive R&D work in millimeter wave radio frequency and AI technology. Through these efforts we created our ultra compact and efficient health monitoring system on a chip or SoC, which measures just 4 by 6.7 millimeters in size. Use of this chip yielded breakthrough advances in blood pressure monitoring, enabling accurate, [indiscernible] and automated tracking. We announced the results of a blood pressure clinical study in October 2023, where our prototype achieved an overall mean absolute difference for MAD of 5.9 millimeters of mercury well below the 7-millimeter mercury MAD required for an FDA recognized standard for wearable couplets blood pressure monitoring devices. The results of this clinical trial were a clear catalyst for investment by the Tier 1 medical device company. Looking ahead, we're also evaluating AI-based individual calibration methods to further enhance the future performance of our prototype. Ultimately, we expect blood pressure monitoring will be a significant addition to incorporate into a new product that supplements the suite of analytes we currently offer in Evie. In addition, we believe our single-chip technology can be implemented in products designed to aid in the treatment of patients with multiple chronic conditions, including diabetes, where our platform is being evaluated for noninvasive blood glucose monitoring. Our studies demonstrated that our millimeter wave RF technology surpasses traditional optical sensors and provide high-fidelity data and reliable readings with the ease of continuous data collection. We look forward to additional clinical testing later this year, leveraging the RF chip. With that, I'll now hand the call over to Jay for the financial review.
Jeremy Cogan: Thanks, John. Earlier this afternoon, we closed on a $24 million private placement, including a $3 million equity investment by a Tier 1 multibillion-dollar global medical device company and more than $36 million -- $3.6 million in investment by insiders to include members of the company's management team and Board of Directors. Going forward, we believe we now have the resources to judiciously drive our D2C business, launch Evie Med, target B2B and accelerate clinical trials and pre-commercial work related to our proprietary RF technology. Importantly, with these funds now on our balance sheet, our production partners committed to instituting a turnkey process. which should free up both working capital and people resources for Movano Health as our manufacturing partner will now purchase an inventory raw materials, parts and finished goods. We expect this will be a significant benefit for the company. Moving to our financial commentary. While the launch of Evie Ring in late 2023 began the Movano Health transition to a commercial stage company, shipments commenced in January 2024, and revenue will be recognized as a result in 2024. In our first quarter results, we will begin to report revenue, which we expect to be nominal as we paused order intake in mid-February. That said, one of the things we've learned since launching Evie Ring in November is that there is significant demand for the product. The company generated over $1 million in sales during a very efficient Black Friday holiday launch period, given capital constraints, we ceased all paid marketing as of December 1, and we continue to see a steady flow of orders through mid-February when we're taking new orders. From December through March, we prioritized capital preservation and actions to meet production and customer service needs. Looking ahead with an improved capital position and operational improvements across product, manufacturing and customer service, we were building inventory in preparation for relaunching Evie. We'll also be moving with intention along the regulatory pathway as we work toward receiving our first FDA clearance and securing initial B2B contracts with health care partners. For the fourth quarter of 2023, Movano Health reported an operating loss of $6 million, and that compared to an operating loss of $8 million in the year ago period. Our cash burn in the fourth quarter of 2023 was $5.4 million, which was inclusive of costs for the Evie Ring launch and expenses related to our FDA submission as well as other timing considerations. In November, we raised $4.1 million in gross proceeds in an equity financing that partially offset the cash burn. At December 31, 2023, we had $6.1 million of cash and cash equivalents on our balance sheet. And as noted earlier, we closed on the $24 million private placement earlier this afternoon. As that concludes our formal remarks, we'd be glad to take your questions. Operator?
Operator: [Operator Instructions]. We'll now be conducting a question-and-answer session.
Unidentified Company Representative: It doesn't look like we have any questions on the phone line, operator. Let's start with the webcast. And I have a few questions here, which I can begin to ask. And maybe, John, if you can start with this first question, are there any additional updates that you can provide as it relates to our first 510(k) application?
John Mastrototaro: Yes. First off, as I mentioned in the earlier remarks, we've made tremendous progress with the clinical work on the Evie Ring. The results from our latest trial were exceptional, and it was very interesting to see that one of the hospital devices actually did not meet the FDA accuracy criteria. In my experience in working with the FDA, obviously, the clinical results are critically important. And so we feel really good about that. In addition, we've had numerous discussions with the FDA. They have been working with us very collaboratively and we're pleased with that. And we have addressed all of the questions that they have brought to our attention. And so we will be filing the new information to the agency later this month. And as I mentioned, we do expect to have a decision from the agency in July, but I do feel pretty good about where we are based upon the discussions that we've had to the state and the clinical data that we achieved in the latest study.
Unidentified Company Representative: Okay. And there's another question here in the webcast about Evie Med looking for a little bit more information about what Evie Med and how that compares to Evie Ring as a wellness product.
John Mastrototaro: So the Evie Med hardware is essentially the same as the Evie wellness device that we launched already. But there are some differences. When you have a medical device FDA reviews the labeling in detail. And obviously, for the medical device aspects of it, there are some differences between the 2. And then secondly, beyond just the labeling, the app experience is different. We've separated out the wellness metrics from the medical metric of what like a pulse oximeter would provide as part of the app experience. And that's based upon some discussions that we've had with the agency as well. So we feel pretty good about that. Naturally, we do look forward to talking more about this in the future. And certainly, as we move forward and have more feedback from the agency. Jay, maybe you could spend a moment though and talk a little bit about some of the things that we're thinking about related to pricing and whatnot.
Jeremy Cogan: Sure. I would say, given that Evie Med will be an FDA-cleared device, we would expect it to be sold at a premium relative to the Evie Ring. And on top of that, across the B2B space, we see a variety of opportunities to have a recurring revenue stream database revenue, for example, whereas with the Evie Ring, it's a product sale. And so we look forward to talking more about that in the future as well.
Unidentified Company Representative: Okay. Let's go on to the next question. John or Michael, maybe you can take an update here. The question is related to strategics or this existing strategic partner. If you can talk a little bit about where things stand with potential partners at this stage.
Michael Leabman: Sure. Thank you, John. Yes. So that's a great question. Just this month, we've had 2 large strategic partners, one in the RPM channel. The other in the payer channel, wrapping up their beta tests. We continue to engage our first set of beta partners from last year in channels ranging from medical device to pharma. And they are all very much looking forward to our FDA clearance coming up in the July time frame. And then most recently coming off our announcement of our cuffless blood pressure clinical study results, we have a whole new tranche of large strategic partners wanting to work with us in channels ranging from pharma to medical device to everything in between. John?
John Mastrototaro: No, that's fine. I think we should move on to the next question. Go ahead, Jay.
Jeremy Cogan: Great. Maybe this is for Tyla and Stacy. What has been the customer response to you bring thus far? Can you tell us how users are engaging with the app about their broader user experience.
Tyla Bucher: Yes, I can kick us of. So John already mentioned, we faced a number of operational and customer service challenges out launch, which was obviously frustrating for our customers and very frustrating for us as well as our goal has always been to provide a best-in-class user experience across the board. But despite these initial setbacks, we're still committed to fulfilling this goal, and we have received a tremendous amount of invaluable feedback and support from our early adopters, all of which we are implementing in our go-forward planning. Additionally, the media does continue to review us very positively, which is driving traffic and awareness for the Evie brand. And as John noted, we have over 8,000 people signed up for updates since we paused the site with no paid marketing at all. So I mean this, coupled with our planned media efforts, our influencer program and our upcoming launch on a new social channel will set us up for success once we're ready to start taking orders again. In addition to opening the store back up, our ongoing focus now that we're resourced will be to shore up our customer service and delivery response time, expand our engagement strategy for our existing members and build out our product offering to include new features and insights. And actually, with that, I will turn that over to Stacy.
Stacy Salvi: Thanks, Tyla. So from a strategic product perspective, we're really pleased to see our users highly engaged with the app and using the ring and app as expected. Of course, we're focused on delivering the high-quality experience our users deserve with attention paid to improving sleep and the activity feature first. We're also rolling out the Insights experience as we speak and excited to develop this important feature, which really personalizes and contextualizes the data from the ring in the coming months.
Jeremy Cogan: Seeing that there are still no questions on the phone lines. I'm going to ask a few more questions here from the webcast Q&A. And either John or maybe, Tyla, there's a few questions about when we're going to start shipping Evie rings again. What do we need to see before we start taking new orders going forward?
John Mastrototaro: Yes. First off, with the new funding, we're focused on optimizing our production processes and delivery times as well as ordering raw materials, components and working on the overall ring improvements. We're currently working with our vendors to order the materials we need to satisfy increased demand. But we're going to continue to hold on taking new orders until we ensure that we can establish and maintain an ongoing inventory of about a month or 2 by skew at all times. We want to be able to move forward to be able to fulfill orders almost immediately when they come in. Tyla, do you have anything you'd like to add?
Tyla Bucher: No, I think it's good. I think the key is that we're continuing to focus on this goal of making sure that it is a best-in-class customer service experience when people do order the ring. And in the interim, we're going to be focused really heavily on driving engagement with the consumers that we do have. So then when we opened up, there's really solid word of mouth.
Jeremy Cogan: Okay. We've got a few here about blood pressure and prototypes for blood pressure and the glucose initiatives. So John made there for you. Can you tell us a little bit more about what this the blood pressure clinical trial that we've been referring to from last fall, what do the results really mean? And how long will it be before a blood pressure product could potentially make it to the market?
John Mastrototaro: Yes. First off, one thing that was really critical about the work on blood pressure was that we demonstrate that the chip that we produced working in concert with GLOBAL foundries was fully functional and able to provide higher resolution signals that we could use to determine blood pressure values. And so that was a real key for us. And the fact that we were able to gain an accuracy in the study that was commensurate with what the FDA guidelines request of a product like this was really important to us. And it really formed the basis for the investment by this Tier 1 multibillion dollar medical device company because blood pressure is such a huge problem. It's probably -- if you could have one analyte that you could be measuring continuously at home. Blood pressure is first up, half of people over the age of 20 suffer from a hypertension or pre-hypertensive and it's the leading cause of heart disease and stroke and other things. So it's the big grand daddy of them all. Glucose is a bit behind that. And of course, we're making progress there as well. But this is critical. And then in terms of how long to the market, we just completed that feasibility trial with a prototype system. We have already made some enhancements in the layout of the components on the board to optimize it for a next round of studies. And so throughout the course of this year, we'll be conducting more clinical work. We'll be evaluating the product in more like a consumer type form factor. Moving forward, we have done all of our initial studies on the wrist versus the finger, and we will continue to do so, but we may do some experimental work looking at our ability to monitor blood pressure on the finger. And through the course of this time, we will continue to develop what the overall consumer-oriented form factor would look like. as well as continue to not only generate clinical evidence, but look at longitudinal tracking of blood pressure. So we look forward to updating you more over time now that we have the resources that allow us to really put more behind these efforts for blood pressure because it is one of our top initiatives in the company.
Jeremy Cogan: And John, I don't think you mentioned it in those comments there, but there's another question here regarding blood pressure and also regarding glucose monitoring and wondering if we would expect the first product to be in a ring or possibly a band or some other form factor.
John Mastrototaro: One of the things we have not evaluated for blood pressure anywhere, but the wrist at this point. We basically focus the RF energy at the radial artery of the wrist for the measurements. We get really clean, very nice pulse pressure wave forms using that. We're going to have to look at whether or not we could do it on the finger. We know that chip is small enough to fit inside a ring that could be used on the finger, but we have not evaluated that site. But we do know that we want to be able to assess a waveform that's coming from an arterial source. As it relates to glucose, it's a little bit more open. Quite frankly, if you're aware of the existing CGMs and something I worked on for a lot of my career, they're done in the inner -- looking at the interstitial fluid. And really, we're looking at interstitial changes in signals based on the RF signature for glucose. So we are also looking at whether we could for glucose monitoring, use other sites of making the measurement. I think there's more flexibility with glucose than there is for blood pressure.
Jeremy Cogan: Great. And maybe Stacy or Tyla, there's a question about Apple Health and when Evie is planning on connecting to Apple Health in the future.
Stacy Salvi: I can take this one. Thank you so much for the question. This is certainly near the top of our list. We know our users are also likely Apple products users, of course. And so as we consider the kind of landscape of opportunity out there and where we want to focus our attention, this one is on the short list. I can say that. I can't give an exact date, but certainly something that we are looking at.
John Mastrototaro: Great. And I think the last question for today will be one that I can actually answer. How long will the cash you just raised last. And what we would first want to say is, look, we're incredibly pleased with the results of the $24 million capital raise that we closed earlier this afternoon. As we've mentioned, we got a $3 million strategic seed investment by a Tier 1 multibillion global medical device company. And we also saw very strong demand from existing shareholders and new institutional investors and clearly had significant participation from insiders including members of the management team and the Board of Directors. The capital is going to be able to provide us with the ability to proceed along our major initiatives, including the regulatory pathway to the FDA clearance, that can help us accelerate our blood pressure clinical studies and work around noninvasive glucose monitoring and as we've also been discussing begin to scale commercial production. Okay. With that, operator, I think we are ready to end today's call. Thank you.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.